Navigation Links
BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
Date:6/23/2011

ww.bmrn.com/">www.BMRN.com. Date: June 23, 2011Time: 9:30 a.m. ET U.S. / Canada Dial-in Number:  866.713.8567International Dial-in Number:  617.597.5326Participant Code:  90826881Replay Dial-in Number:  888.286.8010Replay International Dial-in Number:  617.801.6888Replay Code:  97445483About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers.
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioMarin to Present at the William Blair Growth Stock Conference
2. BioMarin to Present at the Jefferies Global Healthcare Conference
3. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
4. BioMarin Announces First Quarter 2011 Financial Results
5. BioMarin to Present at the Deutsche Bank Healthcare Conference
6. BioMarin to Present at the Barclays Global Healthcare Conference
7. BioMarin to Present at the Cowen Health Care Conference
8. BioMarin to Present at the Citi Global Healthcare Conference
9. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
10. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
11. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... protection, repair and regeneration, today announced that J.J. ... to present a corporate overview at two upcoming investor ... the SeeThruEquity 4 th Annual Microcap Conference on ... City at 11:00 am EDT.  A webcast ...
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, 2015 ... CSL Behring its 2015 Corporate Leadership Award as ... science and improving the care of the bleeding disorders community.  ... and Managing Director, CSL Limited, during the NHF Annual Spring ... May 21. "The National Hemophilia Foundation is dedicated ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4
... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... “It’s like learning an new ... Vice President of Clinical Operations/Education and Training at ... impacts how care is coded and reimbursed.” , ... care reimbursement, operations and compliance consulting, as well ... launches a new series of day-long seminars on ...
(Date:5/22/2015)... Carnegie Science Center and ... partnership to develop BodyTech, a dynamic, three-pronged health and ... a new exhibit at the Science Center called BodyWorks, ... new traveling science show, Anatomy Adventure, which will hit ... Designed to explore a wide range of topics surrounding ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning ... some tips to help promote safe travel. , According to ... traffic fatalities this Memorial Day weekend. Amica is sharing the ... Association: , , Always wear a ... seatbelt, whether they’re driving or riding along as a passenger. ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship of ... is in his second year of racing in the professional ... Fire Department in Missoula, MT. He entered the triathlon scene ... career, he has had 15 1st Place finishes. In his ... in all seven of his 2014 races, including two 2nd ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... Poor sleep tied to quality of life, depression, study says ... common among elderly people who live in assisted living facilities, ... associated with declining quality of life and increased depression. , ... when they,re no longer able to live independently but do ...
... while longer-term risks are uncertain , FRIDAY, May 7 ... Gulf of Mexico and now some barrier islands off ... environment while posing risks to public health, experts say. ... headaches, nausea, coughing and throat irritation, according to the ...
... from a corticosteroid regimen have fewer cardiovascular events ... survival rates and reducing early mortality, according to ... of Cincinnati (UC) transplantation researchers. Researchers with ... medicine are presenting the work at the American ...
... explain different outcomes for women with similar-looking tumors, expert ... of breast cancer into subtypes can be achieved through ... U.S. researchers say. , They analyzed 32 gene expression ... and six classification models. , "We studied these models ...
... breast cancer , C.B. Agborsangaya, FINLAND, As women ... the incidence of pregnancy-associated breast cancer is expected ... p53 autoantibody-positive pregnant women may be useful in ... cancer. Abstract 92P: Post traumatic stress disorder ...
... a benign tumor of mesenchymal origin which is mostly ... 2/3 of small bowel occlusion caused by up to ... frequent benign tumor that causes invagination in its submucous ... form. However, multiple lipomas within the intestinal duplication canal ...
Cached Medicine News:Health News:Sleepless Nights Plague Assisted Living Residents 2Health News:Gulf Oil Spill Could Threaten Human Health 2Health News:Gulf Oil Spill Could Threaten Human Health 3Health News:Study finds post-transplant patients off steroids have fewer cardiovascular events 2Health News:Study finds post-transplant patients off steroids have fewer cardiovascular events 3Health News:Simple Test May Identify Breast Cancer Subtypes 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 3
... its synthetic bone substitute Ossatura. Developed at Isotis, ... material, i.e. a material that is designed to ... the musculo-skeletal system that results in bone growth. ... and reduces in part or entirely the need ...
Schuknecht-Weitlaner retractor, sharp, angled arms....
Beckman-Weitlaner retractor, blunt, with hinged arms, 6 1/2"....
Daubenspeck sharp curette, 8....
Medicine Products: